Different Microfluidic Environments for In Vitro Testing of Lipid Nanoparticles against Osteosarcoma

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Lipid nanoparticles offer potential for targeted drug delivery in cancer therapy.
• Methodological challenges in validating nanovehicles have hindered clinical translation.
• Methotrexate (MTX) is a chemotherapy agent used in treating various cancers, including osteosarcoma.

Purpose of the Study:

• To evaluate the efficacy of methotrexate (MTX) encapsulated in lipid nanoparticles using a dynamic microfluidic platform.
• To compare the effectiveness of MTX-loaded nanoparticles against free MTX in a tumor-mimicking microenvironment.
• To assess the potential of MTX-lipid nanoparticles as a novel therapy for pediatric osteosarcoma.

Main Methods:

• Utilized a dynamic microfluidic platform to simulate tumor microenvironments.
• Assessed the viability of osteosarcoma cells exposed to free MTX and MTX-loaded lipid nanoparticles.
• Investigated the effects under conditions of cell media recirculation.
• Evaluated nanoparticles in different concentrations and tumor-mimicking conditions.

Main Results:

• MTX-loaded nanoparticles significantly increased osteosarcoma cell death compared to free MTX.
• Recirculation of MTX-nanoparticles led to a 50-fold greater reduction in cell population than free MTX at 150 µM.
• At 15 µM, MTX-nanoparticles reduced cell numbers by 60 and 100 points more than equivalent free drug doses.
• The microfluidic model demonstrated superior efficacy of encapsulated MTX.

Conclusions:

• MTX-loaded lipid nanoparticles represent a more effective therapeutic strategy than free MTX for osteosarcoma.
• Dynamic microfluidic platforms are valuable tools for validating nanomedicines in physiologically relevant conditions.
• This nanotechnology holds promise for improved pediatric osteosarcoma treatment.